In contrast, VHIO179, a tumour carrying BRCA1 germline truncation and previously shown to be resistant to treatment with PARPi due to an inactivating mutation in the MAD2L2 (REV7) gene (Bruna et al, 2016; Cruz et al, 2018), was hypersensitive to pyridostatin. Here, MAD2L2 is linked to neoplasm.